Literature DB >> 21335102

An empirical approach to model selection through validation for censored survival data.

Ickwon Choi1, Brian J Wells, Changhong Yu, Michael W Kattan.   

Abstract

Medical prognostic models can be designed to predict the future course or outcome of disease progression after diagnosis or treatment. The existing variable selection methods may be precluded by full model advocates when we build a prediction model owing to their estimation bias and selection bias in right-censored time-to-event data. If our objective is to optimize predictive performance by some criterion, we can often achieve a reduced model that has a little bias with low variance, but whose overall performance is enhanced. To accomplish this goal, we propose a new variable selection approach that combines Stepwise Tuning in the Maximum Concordance Index (STMC) with Forward Nested Subset Selection (FNSS) in two stages. In the first stage, the proposed variable selection is employed to identify the best subset of risk factors optimized with the concordance index using inner cross-validation for optimism correction in the outer loop of cross-validation, yielding potentially different final models for each of the folds. We then feed the intermediate results of the prior stage into another selection method in the second stage to resolve the overfitting problem and to select a final model from the variation of predictors in the selected models. Two case studies on relatively different sized survival data sets as well as a simulation study demonstrate that the proposed approach is able to select an improved and reduced average model under a sufficient sample and event size compared with other selection methods such as stepwise selection using the likelihood ratio test, Akaike Information Criterion (AIC), and lasso. Finally, we achieve better final models in each dataset than their full models by most measures. These results of the model selection models and the final models are assessed in a systematic scheme through validation for the independent performance.
Copyright © 2011 Elsevier Inc. All rights reserved.

Mesh:

Year:  2011        PMID: 21335102     DOI: 10.1016/j.jbi.2011.02.005

Source DB:  PubMed          Journal:  J Biomed Inform        ISSN: 1532-0464            Impact factor:   6.317


  10 in total

1.  Sexual Assault Victimization and Mental Health Treatment, Suicide Attempts, and Career Outcomes Among Women in the US Army.

Authors:  Anthony J Rosellini; Amy E Street; Robert J Ursano; Wai Tat Chiu; Steven G Heeringa; John Monahan; James A Naifeh; Maria V Petukhova; Ben Y Reis; Nancy A Sampson; Paul D Bliese; Murray B Stein; Alan M Zaslavsky; Ronald C Kessler
Journal:  Am J Public Health       Date:  2017-03-21       Impact factor: 9.308

2.  Comprehensive analysis of the immune implication of FABP4 in colon adenocarcinoma.

Authors:  Dabin Wu; Ling Xiang; Linglong Peng; Haitao Gu; Yunhao Tang; Haoyun Luo; Hang Liu; Yaxu Wang
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

3.  Validation of the 8th edition of the TNM staging system in 3,950 patients with surgically resected non-small cell lung cancer.

Authors:  Jae Kwang Yun; Geun Dong Lee; Hyeong Ryul Kim; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park; Sehoon Choi
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

4.  Survival Prediction and Feature Selection in Patients with Breast Cancer Using Support Vector Regression.

Authors:  Shahrbanoo Goli; Hossein Mahjub; Javad Faradmal; Hoda Mashayekhi; Ali-Reza Soltanian
Journal:  Comput Math Methods Med       Date:  2016-11-01       Impact factor: 2.238

5.  MRI-based radiomics signature is a quantitative prognostic biomarker for nasopharyngeal carcinoma.

Authors:  Xue Ming; Ronald Wihal Oei; Ruiping Zhai; Fangfang Kong; Chengrun Du; Chaosu Hu; Weigang Hu; Zhen Zhang; Hongmei Ying; Jiazhou Wang
Journal:  Sci Rep       Date:  2019-07-18       Impact factor: 4.379

6.  OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates.

Authors:  Mancheng Gong; Yongxiang Li; Erlin Song; Miaoyuan Li; Shaopeng Qiu; Wenjing Dong; Runqiang Yuan
Journal:  Front Immunol       Date:  2022-02-15       Impact factor: 7.561

7.  A Predictive Model for Prognosis and Therapeutic Response in Hepatocellular Carcinoma Based on a Panel of Three MED8-Related Immunomodulators.

Authors:  Xiaojun Jin; Yongfei Song; Zhanglu An; Shanshan Wu; Dihui Cai; Yin Fu; Chuanjing Zhang; Lichao Chen; Wen Tang; Zequn Zheng; Hongsheng Lu; Jiangfang Lian
Journal:  Front Oncol       Date:  2022-04-26       Impact factor: 5.738

8.  Comprehensive Analysis of the Immune Implication of AKAP12 in Stomach Adenocarcinoma.

Authors:  Zhiquan Xu; Ling Xiang; Linglong Peng; Haitao Gu; Yaxu Wang
Journal:  Comput Math Methods Med       Date:  2022-09-13       Impact factor: 2.809

9.  Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.

Authors:  Jae Kwang Yun; Youngwoong Kim; Geun Dong Lee; Sehoon Choi; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park; Hyeong Ryul Kim
Journal:  Cancer Med       Date:  2022-04-17       Impact factor: 4.711

10.  Feature selection through validation and un-censoring of endovascular repair survival data for predicting the risk of re-intervention.

Authors:  Omneya Attallah; Alan Karthikesalingam; Peter J E Holt; Matthew M Thompson; Rob Sayers; Matthew J Bown; Eddie C Choke; Xianghong Ma
Journal:  BMC Med Inform Decis Mak       Date:  2017-08-03       Impact factor: 2.796

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.